NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering

Rhea-AI Summary

NanoViricides (NYSE American: NNVC) entered a securities purchase agreement with a single fundamental institutional investor for a registered direct offering of 2,516,339 common shares (or pre-funded warrants in lieu) plus accompanying warrants to buy 2,516,339 common shares, for expected gross proceeds of approximately US$3.8 million.

Each whole warrant is exercisable at US$1.75 per share and will expire five and a half years from issuance. Closing is expected on or about July 27, 2026, subject to customary conditions. According to NanoViricides, the securities are being issued under an effective Form S-3 shelf registration declared effective on June 15, 2026, with a prospectus supplement to be filed. The company also highlights its clinical-stage broad-spectrum antiviral NV-387, which has US FDA Orphan Drug Designation that could provide seven years’ market exclusivity, tax credits, and fee exemptions upon approval.

Positive

• Registered direct offering gross proceeds of approximately US$3.8 million before fees
• Accompanying warrants for 2,516,339 shares at US$1.75, expiring in 5.5 years
• Single institutional investor provides committed counterparty for the financing
• NV-387 Orphan Drug Designation with potential 7-year exclusivity and tax credits

Negative

• Equity and warrant issuance implies dilution for existing NNVC shareholders
• Net proceeds will be lower than US$3.8 million after fees and expenses

Market reaction after 3.8M registered direct offering: NNVC -3.27% in the Jul 24 session

-3.27%

3 alerts

-3.27% Session close to close

$34.93M Market Cap

0.1x Rel. Volume

In the Jul 24 session, NNVC declined 3.27%, reflecting a moderate negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The two prior offering events recorded negative 24-hour reactions of -3.64% and -14.94%. That histor...

Analysis

The two prior offering events recorded negative 24-hour reactions of -3.64% and -14.94%. That history frames this financing as a recurring capital-raising event; the effective S-3 shelf and potential dilution warrant monitoring.

Key Figures

Gross proceeds: ~$3.8 million Common shares: 2,516,339 shares Accompanying warrants: 2,516,339 shares +5 more

8 metrics

Gross proceeds ~$3.8 million Registered direct offering, before fees and expenses

Common shares 2,516,339 shares Shares offered, or pre-funded warrants in lieu thereof

Accompanying warrants 2,516,339 shares Common shares underlying accompanying warrants

Warrant exercise price US$1.75 per share Each whole warrant

Warrant expiration Five and half years From the date of issuance

Expected closing July 27, 2026 Subject to customary closing conditions

Shelf effectiveness June 15, 2026 Form S-3 declared effective by the SEC

Market exclusivity 7 years Potential benefit described for NV-387 upon approval

Previous Offering Reports

2 past events · Latest: May 18 (Negative)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
May 18	Registered direct offering	Negative	-3.6%	Registered direct financing raised approximately $2 million with shares and warrants.
May 15	Registered direct pricing	Negative	-14.9%	Pricing of approximately $2 million offering included $1.75 warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The two prior offering events both had negative 24-hour reactions: -3.64% and -14.94%.

Key Terms

registered direct offering, pre-funded warrants, shelf registration statement, securities purchase agreement

4 terms

registered direct offering financial

"gross proceeds of approximately US$3.8 million in a registered direct offering"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

pre-funded warrants financial

"common stock (or pre-funded warrants in lieu thereof)"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

shelf registration statement regulatory

"pursuant to an effective shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

securities purchase agreement financial

"entered into a securities purchase agreement with a single fundamental institutional investor"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SHELTON, CT / ACCESS Newswire / July 24, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape, today announced it has entered into a securities purchase agreement with a single fundamental institutional investor for the purchase and sale of 2,516,339 shares of common stock (or pre-funded warrants in lieu thereof), together with accompanying warrants to purchase 2,516,339 shares of common stock for gross proceeds of approximately US$3.8 million in a registered direct offering (the "Offering"). The common shares are being sold in combination with an accompanying full warrant (with each whole warrant being exercisable into one common share of the Company). Each whole warrant has an exercise price of US$1.75 per share and will expire five and half years from the date of issuance.

D. Boral Capital LLC is acting as the exclusive placement agent for the Offering.

The closing of the Offering is expected to occur on or about July 27, 2026, subject to the satisfaction of customary closing conditions. The Company expects to receive aggregate gross proceeds of ~$3.8 million from the Offering, before deducting placement agent fees and other related expenses.

The ordinary shares (or pre-funded warrants in lieu thereof) are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-296790), which was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on June 15, 2026.

A prospectus supplement describing the terms of the proposed registered direct offering will be filed with the SEC. Once filed, it will be available on the SEC's website at http://www.sec.gov and on the Company's website at https://www.nanoviricides.com/. A copy of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained, when available, from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, or by telephone at (212) 404-7002, or by email at dbccapitalmarkets@dboralcapital.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About NanoViricides

NanoViricides, Inc., is a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape. Its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted an "Orphan Drug Designation" (ODD) by the US FDA Office of Orphan Products Development (OOPD). This could provide 7 years market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval. NV-387 is a revolutionary antiviral that we believe will be the drug offered at "first visit" when the patient presents to a doctor with any respiratory viral illness. NV-387 was also found to be highly effective in lethal animal infection models of Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles.

Forward-Looking Statements

Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by the use of words such as "may," "will," "plan," "should," "expect," "anticipate," "estimate," "continue," or comparable terminology. Such forward-looking statements are inherently subject to certain risks, trends, and uncertainties, many of which the Company cannot predict with accuracy and some of which the Company might not even anticipate and involve factors that may cause actual results to differ materially from those projected or suggested. These risks include, but are not limited to, the ability to complete the offering on the terms described or at all, the ability to satisfy customary closing conditions, market conditions, regulatory developments affecting the digital asset and stablecoin industries, and other risks described in the Company's filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements and are advised to consider the factors listed above together with the additional factors under the heading "Risk Factors" in the Company's Annual Reports on Form 20-F, as may be supplemented or amended by the Company's Reports of a Foreign Private Issuer on Form 6-K. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information, or otherwise.

Contacts:

For Inquiries, Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

SOURCE: NanoViricides

View the original press release on ACCESS Newswire

FAQ

What are the key terms of NanoViricides (NNVC) July 2026 registered direct offering?

NanoViricides agreed to sell 2,516,339 common shares or pre-funded warrants, plus equal-number warrants, for gross proceeds of about US$3.8 million. According to NanoViricides, each warrant is exercisable at US$1.75 per share for five and a half years.

How will the NNVC July 2026 offering affect existing NanoViricides shareholders?

The offering adds 2,516,339 new shares (or equivalent pre-funded warrants) plus warrants for another 2,516,339 shares, increasing potential share count. According to NanoViricides, this equity financing raises about US$3.8 million before fees, implying dilution for current holders.

When is the closing date for NanoViricides (NNVC) US$3.8 million offering?

Closing is expected on or about July 27, 2026, subject to customary closing conditions. According to NanoViricides, the transaction is a registered direct offering to a single fundamental institutional investor under an effective Form S-3 shelf registration.

What are the warrant terms in NanoViricides (NNVC) July 2026 financing?

Each whole warrant allows purchase of one NanoViricides common share at an exercise price of US$1.75 per share. According to NanoViricides, these warrants will expire five and a half years from their date of issuance, adding potential future dilution.

Under which SEC registration is the NanoViricides (NNVC) offering being made?

The securities are offered under an effective shelf registration statement on Form S-3, No. 333-296790. According to NanoViricides, this registration was declared effective by the SEC on June 15, 2026, and a prospectus supplement will describe final terms.

What is NanoViricides’ NV-387 drug and its FDA Orphan Drug Designation?

NV-387 is NanoViricides’ clinical-stage broad-spectrum antiviral candidate with US FDA Orphan Drug Designation. According to NanoViricides, this designation could provide seven years’ market exclusivity, clinical trial tax credits, and certain fee exemptions upon potential approval.

Who is the placement agent for the NanoViricides (NNVC) July 2026 offering?

D. Boral Capital LLC is acting as the exclusive placement agent for the registered direct offering. According to NanoViricides, investors can request the prospectus supplement and base prospectus from D. Boral Capital’s New York office or via telephone and email contacts provided.